About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Webinar on European Patent Prosecution & Litigation | Main | USPTO Inventor Info Chat Webinar on MyUSPTO and USPTO.gov Accounts »

January 12, 2019

Webinar on Biologics and Biosimilars

Strafford #1Strafford will be offering a webinar entitled "Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation" on January 22, 2019 from 1:00 to 2:30 pm (EST).  Shana K. Cyr and Mark J. Feldstein of Finnegan Henderson Farabow Garrett & Dunner and Kurt R. Karst of Hyman Phelps & McNamara will provide essential updates on FDA practice and patent law relating to biologics and biosimilars, and will discuss the current state of and recent changes to FDA initiatives, approvals and exclusivities, as well as patent prosecution, post-grant proceedings and litigation.  The webinar will review the following issues:

• What can we learn from FDA's recent guidance on biologics and biosimilars?
• How does FDA's recent guidance impact patent strategy?
• Should your patent strategy for biologics differ from your approach for small molecule drugs?

The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

Posted at 10:07 PM in Conferences & CLE's |

Comments

Verify your Comment

Previewing your Comment

Posted by:  | 

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)

February 2019

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28    

Categories

Archives

More...